InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Net Income

Bottom-line profit after all expenses, interest, and taxes.

InflaRx N.V.NASDAQ: IFRX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -€5.59M, compared with -€8.31M a year earlier. Trailing-twelve-month net income was -€42.91M.

Context

  • Net income amounted to 155582.1% of revenue in FY2025, up 127797.1 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -€14.02M (+69.3%) for the fiscal year ending Dec 2026, a step up from the +0.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€5.59M+47.4% QoQ
Last fiscal yearDec 2025
-€45.63M+0.9% YoY
LTMMar 2026
-€42.91M+4.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.7%+40.5%+7.7 pp
1 year+0.9%+69.3%+68.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
(45.63M) EUR
Year-over-year change
+0.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.0% is the 4th highest of 9, against a peer median of -9.3%.
  • Net income amounts to 146303.9% of revenue for IFRX, versus a peer median of 20922.4%.
IFRX Competitors
Net Income for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.23M USD-45.6%——
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.1M USD+38.9%——
IMAImageneBio IncLTM Mar 2026-$45.07M USD-8.1%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.48M USD-255.0%—86687.5%
ATYRaTyr Pharma, Inc.LTM Mar 2026-$70.03M USD-10.4%—36857.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M USD-34.3%——
STROSutro Biopharma, Inc.LTM Mar 2026-$153.6M USD+37.4%—154.2%
Peer median (excluding IFRX) —-9.3%—20922.4%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.